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I. Introduction
Aspartame is everywhere. It is in our restaurants and in our homes. Mere
mention of the word aspartame or its brand names, NutraSweet and Equal,
engenders a vide variety of reactions amongst consumers. In America, where
evidence of the war against obesity is omnipresent, consumers are not only
sophisticated about low calorie alternatives to their favorite foods; they have
begun to demand them. As the market desire for these products grows at
an exponential rate, it becomes increasingly acceptable to order lower calorie
meal options in restaurants. Indeed, many restaurants have begun to cater to a
demographic that has money to spend and a desire to be thin. Correspondingly,
the use of aspartame as an every day tabletop sweetener has blossomed. It has
become unusual to be served a hot beverage such as coee or tea in a restaurant
without both sugar and NutraSweet or Equal, both brand names for aspartame.
Furthermore, the use of non-sugar sweeteners has moved from a female-only
habit to one generally embraced by more health-conscious men and women.
As drinking diet soda and using non-sugar sweeteners has become increas-
ingly mainstream, such items have replaced sugar even in the diets of many
people who do not consider themselves overweight or dieting. NutraSweet has
provided one way of getting the avor of sugar while saving on extra calories
that can now be spent elsewhere. So, as Americans seem to be becoming in-
1creasingly conscious of their health and weight, the market is promoting ways
of having your cake and eating it too. Low-calorie sweeteners play an enormous
role in this industry.
As the diet industry has grown, some consumers and consumer advocates have
been waging a simultaneous war against what they feel is an industry that
threatens the health of overly trusting and quick x oriented American con-
sumers. Paradoxically, as American's become increasingly concerned about their
waistlines and their general health, these consumer advocates feel an increasing
need to protect citizens from potentially harmful diet products and low-calorie
substitutes for certain foods. Although the Food and Drug Administration
(FDA) regulates the introduction of food additives into the market, some con-
sumer advocates feel that the agency is not doing a sucient job.1
These two opposing tensions, the market desire for low-calorie foods including
sugar substitutes, and the fear of consumer manipulation by a burgeoning indus-
try and a collusive FDA, drive the fascinating history of aspartame. This paper
follows the important hurdles in aspartame's past, including the attempts of its
promoters to gain regulatory acceptance, several safety scares, botched scien-
tic research, scandals, lawsuits and investigations. It also seeks to illuminate
how FDA has dealt with, and participated in the tenacious struggle surrounding
aspartame's regulation, use and safety. Finally, this paper looks to the future
in order to determine if the aspartame debate will soon come to a nal end.
1The Food Additives Amendment, 72 Stat. 1784 (1958) was promulgated to close loopholes
in existing law.
2II. A Brief History of Sugar-Substitutes
In the United States, there has been a longstanding tension between mar-
ket desire for a low calorie sugar substitute and fears about the safety of such
substitutes. Despite the FDA's attempts to allay consumer fears about FDA
approved additives and promote condence in the ability of the agency to bal-
ance the market demands with safety concerns, some consumers have not been
appeased. The two sides of the sugar substitute battle have illuminated real
and fantastical concerns, and spawned a ery regulatory battle that has lasted
over 100 years. Ironically, the FDA has apparently remained fairly neutral in
its role as regulator, despite the passionate protests of the pro-approval and
anti-approval camps.
The sugar substitute industry inception occurred largely by accident in 1879
when two Johns Hopkins University scientists who were hoping to discover a
wonder drug instead found saccharine - a non-nutritive coal-tar derivative that
is 300 times sweeter than sugar.2 By 1907, saccharine was widely used as a
sweetener in canned foods, though just ve years later it was banned from use
as a food additive. With the onset of sugar shortages in World War I, however,
saccharine was again declared safe. With that, saccharine use increased steadily
until the 1950's while the potential adverse eects of the sugar substitute main-
tained a low prole. 3
From the time of its invention, saccharine and the sugar-substitute industry has
2NY Times., March 29, 1997, at page 24; col.1.
3Id.
3been driven by twin American desires: the desire for health and the desire for
beauty. Throughout the centuries, sugar has been linked to many human ills
from cavities and tooth decay, to gout, obesity and heart disease. Instead of cor-
recting the real and imagined negative eects of sugar consumption, however,
sugar-substitutes seem to have merely spawned more health related concerns
while oering only less calories for more sweetness in the American diet. Re-
cently, scientists have stated that no major health problems are in fact directly
associated with eating sugar. Food scientists acknowledge that sugar consump-
tion can contribute to excess calories which in turn may fuel the problems of
obesity, though the introduction of sugar-substitutes has not had a signicant
impact in lowering rates of obesity amongst Americans.4 Diabetics also must
limit sugar consumption since their bodies do not properly metabolize it, but
sugar has not been shown to cause the disease.5
Although health concerns have played a role in promoting the market demand
for sugar-substitutes, the complicit role of American beauty ideals is also signi-
cant. In many ways the American ideals of health and beauty are linked. What
is promoted as beautiful in our society has for the most part been linked to
health. However, as slim and even emaciated bodies have increasingly become
the pinnacles of beauty promoted by the fashion industry, health and beauty
diverge in reality. Even so, companies that promote diet aids and low calorie
substitutes to high calorie foods are careful to make the two ideals seem to be
one and the same. This partially explains the American consumers' voracious
4NY Times, September 5, 1989, at page 1; col 3
5Id.
4appetite for sugar substitutes that has propelled the sugar-substitute industry.
The dynamic history of sugar-substitutes in America cannot be fully understood
without an exploration of the element of fear that has plagued consumers and
nearly tempered the sugar-substitute industry.
Concern over the safety of saccharine became widespread in the 1950's when the
marketing of cyclamate, another sugar-substitute, prompted additional research
on the eects of sweetening agents.6 In 1950 Abbot laboratories introduced a
sweetening tablet designed for diabetics, that contained cyclamate, a chemical
isolated in 1937 when a student working with a fever-reducing drug, icked some
tobacco o his lips and wondered why his ngers tasted so sweet. In 1951 the
FDA approved cyclamate for use in food. Then in 1953, Kirsch Beverages Corp.
introduced the rst diet soda, cyclamate-sweetened No-cal, and the diet-soda
industry was born.7
The use of low-calorie sugar substitutes increased as the Cumberland Packing
Corporation of Brooklyn, New York marketed cyclamate-based Sweet 'n Low
in the bright pink individual-portion wrappers that are still recognizable to-
day. By 1963, cyclamate, which was often used in combination with saccharine,
was the country's most popular sugar substitute. It was used in canned goods,
baked goods, bacon, toothpaste, mouthwash, lipstick and cereal as well as diet
and non-diet beverages.8 It is not clear whether the cyclamate's use was so
pervasive because of its taste, its lower calorie content per sweetness or the fact
6supra note 2
7Id.
8Id.
5that it was sold at one tenth the price of sugar.9
By 1967, diet soda sales were increasing at a fantastic pace. They had doubled
since 1963 and would quintuple in the next two decades.10 Seemingly in reac-
tion to this explosion of articial-sweetener sales and consumption, the FDA set
forth a recommendation that adults use no more than 3,500 milligrams of cycla-
mate a day, the equivalent of ten cans of diet soda. A FDA report states that
[N]one of the studies reported have established a useful role for non-nutritive
sweeteners as weight-reducing aids...11
This cautionary momentum continued and in 1969 the FDA banned cyclamate
when testing that was done on both saccharine and cyclamate suggested that
large doses of cyclamate caused bladder tumors in laboratory rats. This was
not enough to stie the American desire for low-calorie sweeteners. However, in
the wake of the ban on cyclamate, a saccharine-based table sweetener appeared
on the market. Soon after that, a group of people sued the US Government
on behalf of free and unindentured American citizens for banning cyclamate.12
This suit is one of the rst shots the pro-sweetener, anti-regulation camp took
against government regulation. It marks the beginning of their heated struggle
to keep sweeteners, despite potential health risks, on the market.
III. FDA Announces Proposed Ban on Saccharine
March 1977 brought mayhem to the soft-drink industry. When the FDA be-
9Id.
10Id.
11Id.
12Id.
6came aware of a Canadian study that linked use of saccharin to bladder cancer
in laboratory rats, speculation grew that saccharine would soon be banned.13
The possibility that the widely used sugar substitute would be banned sent
manufacturers scrambling for a way to keep their low-calorie beverages on the
market. At that time, soft-drink manufacturers accounted for 75 percent of the
estimated 5 million pounds of saccharin consumed in the U.S. annually. Despite
the industry's considerable size and inuence, however, it could not dissuade
the FDA from its proposal.
A study that came from the Albany Medical College in Albany, N.Y., report-
ing that saccharin proved to be completely harmless also failed to prevent the
ban.14 Even accounts of numerous calls to the American Diabetes Association,
whose switchboards were ooded with calls from concerned diabetics, could not
persuade the FDA that the need for a sugar substitute was more important than
the safety of consumers.
In fact, under the Delaney Amendment to the Pure Food and Drug Act, the FDA
had little choice but to ban saccharine.15 The amendment mandates that any
product that produces any sign of cancer in test animals or humans is banned.16
Dr. Sherwin Gardner, then acting commissioner of FDA, said the FDA had no
evidence that saccharin has ever caused cancer in human beings, but that the
Canadian tests show unequivocally that this substance can produce malignant
bladder tumors in rats.17 Ironically, despite the Commissioner's initial concerns
13Wash. Post., March 11, 1977, at D9
14Id.
15Supra note 1
16Id.
17Supra note 13
7or the requirements of the Delaney Amendment, Congress overruled FDA's at-
tempt to restrict the use of saccharine.18 The damage to saccharin's reputation
could not be repaired despite the fact that it remained on the market.
What was bad news for saccharine producers and marketers, was a boon to G.
D. Searle (Searle) the manufacturer and patent owner for the sugar-substitute
aspartame. The proposed saccharin ban's repercussions on Wall Street included
a boost in sugar stock prices and $1 jump in Searle's stock which was the most
actively traded stock of the day.19 However, investor condence in Searle, did
not translate into immediate approval of aspartame for market purposes.
IV. Background on Aspartame
The tumultuous history of the food additive aspartame began serendipitously
thirty-ve years ago. On the day that James M. Schlatter, a chemist, uninten-
tionally discovered it, he was working on an anti-ulcer drug. As Mr. Schlatter
mixed asparatic acid and phenylalanine, two naturally occurring amino acids
that are the building blocks of protein, he stuck his nger in the mixture and
for some reason decided to taste it. I licked my nger and it tasted good. He
later recalled. And with that, a new, low-calorie sweetener was born.20 What
has happened since that fateful day in 1965 comprises the additive's struggle
from birth to maturity; not unlike a human being moving from inception to
adulthood, aspartame has overcome many hurdles and incited much contro-
versy on its path to a somewhat more stable maturity.
Once aspartame had been more thoroughly tested and successfully reproduced,
18Wash. Post., July 16, 1981, at A10
19Supra note 1
20Wash. Post., September 22, 1982, at E1
8the Skokie, Illinois based pharmaceutical company by the name of G. D. Searle
& Co., employer to Mr. Schlatter, resolved to manufacture it. In 1973, Searle
led a food additive petition for aspartame;21 thus entering aspartame into the
vigorous sugar-substitute competition and beginning a battle that would last
for more than twenty-ve years.
It seemed that the market was ripe for aspartame's introduction. Since the 1969
ban on cyclamate, saccharine manufacturers had held a virtual monopoly on the
low calorie sweetener market. Searle executives saw the potential market for a
new sugar substitute and decided to push for aspartame's approval. Despite the
market demand for low calorie sugar substitutes, however, it would be another
eight years before Searle would eventually receive nal approval for aspartame
in 1981.22
V. FDA Approval
As required by law, Searle petitioned the FDA for approval to market aspartame
as a sweetening agent in certain foods.23 Included in its petition, was extensive
data from the research that had been performed on aspartame, all of which
purported the safety of the additive. After reviewing the data included in the
petition, FDA approved Searle's food additive petition for aspartame on July
26, 1974. The agency then issued a regulation authorizing the use of aspartame
in certain foods and for certain technological purposes.24
2138 Fed. Reg. 5921 (1973)
2246 Fed. Reg. 3828 (1981). FDA's initial approval of aspartame came in 1974, but was
quickly stayed.
23Supra note 21
2439 Fed. Reg. 27317; correction 39 Fed. Reg. 34520 (1974).
9The regulation that the FDA issued approved aspartame for use as a sweetener
in the following foods:
a) Dry, free-owing sugar substitutes for table use (not to include use in
cooking) in package units, not to exceed the sweetening equivalent of 2 tea-
spoonfuls of sugar.
b) Sugar substitute tablets for sweetening hot beverages, including coee
and tea.
c) Cold breakfast cereals.
d) Chewing gum.
e) Dry bases for: i) beverages; ii) instant coee and tea; iii) gelatins, puddings
and llings; and iv) dairy products and toppings. In chewing gum, aspartame
was also approved for use as a avor enhancer in addition to use as a sweetener.25
The Federal Register Notice concerning the regulation stated that of princi-
pal importance to the Commissioner's judgement of aspartame's safety were two
long-term studies of aspartame using rats and dogs. The notice noted that these
two studies revealed a no-eect level (the maximum level of exposure without
a statistically signicant adverse eect) for aspartame at least as high as two
grams per kilogram of body weight. The notice also pointed out that by using a
100-fold safety factor and applying the no eect level to the average 60-kilogram
(about 132 pounds) man, an acceptable intake level would be at least 1.2 grams
of aspartame per day. The general regulation provides that a safety factor of
100 to 1 should be used when applying animal experimentation data to man.26
Based on the restrictions imposed by its regulation on aspartame's use, the FDA
calculated that an individual's daily consumption level would not likely exceed
1.3-1.7 grams per day. These calculations were based on the intake of the fol-
lowing foods sweetened with aspartame shown in the following table. Because
2546 Fed. Reg. 38285; Codied in 21 CFR 172.804.
2621 C.F.R. 121.5
10of the conservative nature of the no-eect level derived from the animal tests
and the 100-fold safety factor employed in relating the tests to man, the FDA
believed that the uses approved by its regulation constituted an acceptable daily
intake of aspartame with a sucient margin of safety.27
Aspartame Approved Use FDA's Estimate of
Daily Intake (grams)
Low High
As a table top sweetener in
coee or tea with an
estimated.083 grams of
aspartame per 8-ounce
cup{ drink 3 cups a day .250 .250
In a dry beverage mix with
.725 grams of aspartame
per quart{ drink 1 quart a/.650 .725
In a gelatin dessert mix
with 1.04 grams of
aspartame per 2 cups dessert
or.26 grams of aspartame
per 1/2 cup serving {eat 1
to 2 servings .260 .520
In a whipped topping with.15
grams of aspartame per 2 cups
topping, or.038 grams of
aspartame per 1/2 cup serving
{eat 1 to 2 servings .038 .075
In a presweetened breakfast
cereal with.083 Grams of
aspartame per 1-ounce cereal
{eat 1 to 1-1/2 ounces .083 .125
Total 1.281 1.695
a/ To arrive at the low estimate, FDA assumed there would be 1.3 grams of
aspartame in 2 quarts of dry beverage mix or.650 per quart.
Despite the somewhat limited approval that was granted at this stage, the
FDA's regulation included three conditions for the use of aspartame regarding
nal product labeling. First, the label of any food containing aspartame was re-
27GAO, Regulation of the Food Additive Aspartame, Rep. No. MWD-76-111 (April 8,
1976)
11quired to bear the following statement: PHENYLKETONURICS: CONTAINS
PHENYLALANINE. This requirement was designed to alert persons who, be-
cause of specic health reasons, need to restrict carefully their phenylalanine
intake. Second, when aspartame was to be used as a tabletop sweetener, its
label was required to bear instructions not to use aspartame in cooking or bak-
ing. This is because aspartame breaks down when exposed to prolonged heat,
resulting in a loss of sweetness. Finally, the regulation required that if a food
containing aspartame purported to be, or was represented, for special dietary
uses, as might be expected of a low calorie product, it was required to be labeled
in compliance with FDA's special dietary foods regulations.28
VI. The First Obstacle
Although the FDA approved Searle's food additive petition for aspartame
in 1974, many hurdles lay ahead.29 Once the Commissioner had publicly con-
cluded that the evaluation of the data in the food additive petition for aspar-
tame, which included approximately 150 studies and other relevant material,
justied amending the food additive regulations to provide for the same use of
aspartame under specied conditions, Searle's troubles began.
The rst obstacle that Searle met came from Dr. John W. Olney, M.D., psychi-
atrist and Professor of Psychiatry at Washington University of St. Louis, and
James S. Turner, author of The Chemical Feast, and co-founder of the Center
for Study of Responsive Law.30 Olney and Turner formally objected to the reg-
28Supra note 25
2939 Fed. Reg. 27,137 (1974)
30See Smyth, The FDA's Public Board of Inquiry and the Aspartame Decision, 1982-1983,
12ulation that authorized the marketing of aspartame as a sweetener in foods.31
Dr. Olney had performed research in animals regarding the toxic eects on the
brain of certain Amino acids, including asparatic acid. Both parties objected
to the use of aspartame in foods, especially those consumed by children. They
asserted that aspartame might cause brain damage resulting in mental retar-
dation, endocrine dysfunction, or both. Turner and Olney also argued that
aspartame could be dangerous to persons with the genetic disorder phenylke-
tonuria (PKU), a disorder that prevents the metabolism of phenylalanine, one
of the amino acids in aspartame.32
These along with other concerns and allegations necessitated a FDA hearing
provided for by 21 U. S. C. 348.33 Instead of having a full evidentiary hearing,
which was customary at the time, the parties waived their right and accepted
a hearing before a public board of inquiry instead.34 This was the rst time
that the FDA had ever used this type of hearing in place of a full evidentiary
hearing. Searle agreed to delay marketing of aspartame temporarily, pending
resolution of the safety questions.35
Dr. Olney, Searle and the Bureau of Foods all submitted lists of nominees for
the public board.36 The acting commissioner then selected a panel that in-
cluded: Walle J. H. Nauta, M.D., Ph.D., Institute Professor, Department of
58 Ind. L.J.633.
31Supra note 24
32[1981 New Matters] FOOD DRUG COSM. L. REP. (CCH) ([In the matter of ] Aspartame)
{38, 124; 46 Fed. Reg. 38,285 (1981) (Commissioner's Final Decision). [Hereinafter cited as
Final Decision].
33Id.
3440 Fed. Reg. 56,907 (1975).
35Final Decision Supra note 3 at 38,285.
36Final Decision, supra note 3, at 38, 736; 46 Fed. Reg. 38,286.
13Psychology and Brain Science, Massachusetts Institute of Technology; Peter J.
Lampert, M.D., Professor and Chairman, Department of Pathology, University
of California (San Diego); and Vernon R. Young, Ph.D. Professor of Nutritional
Biochemistry, Department of Nutrition and Food Science, Massachusetts Insti-
tute of Technology. Dr. Nauta was the Chairman of the board.37
Before the board could hold a hearing regarding the safety of aspartame as a
food additive in response to Olney and Turner's allegations, however, Searle's
quest for aspartame approval hit another snag. Preliminary results from an au-
dit of the records of certain animal studies conducted by or for Searle, including
studies on aspartame, indicated a need for a comprehensive review of the authen-
ticity of the aspartame research data. Apparently, the audit of Searle's clinical
methods revealed sloppy research, including some research that was being done
on aspartame.38 The negative publicity that surrounded Searle's clinical meth-
ods bolstered consumer criticism of aspartame, and further clouded the safety
issues that had not yet been addressed. Alexander Schmidt, then FDA com-
missioner, noted that the FDA audit revealed dierent discrepancies of dierent
kinds.39 Pursuant to 21 U. S. C. 348(e), FDA formally stayed the regulation
authorizing the marketing of aspartame.40
Once the regulation that approved the use of aspartame was stayed, and a task
force was convened, the FDA began to consider methods of authenticating the
studies previously submitted by Searle.41 The FDA decided to authenticate the
37Id.
38Wall St. J., July 21, 1975, at 4, col. 3.
39Id., Dec. 5, 1975, at 8, col. 3.
4040 Fed. Reg. 56907.
41131 Cong. Rec. S10800-01 (Publication page references not available).
14study through the use of a non-government panel of experts that they required
Searle to fund.42 With the knowledge and approval of Searle, the aspartame
data in fteen pivotal studies was thoroughly audited to determine its authen-
ticity. According to FDA records, the FDA audited three of these studies, and
twelve of the studies were audited by the Universities Associated for Research
and Education in Pathology, Inc. (UAREP). The audit took over two years to
complete. Upon its conclusion, UAREP had determined that the studies were
authentic. FDA agreed with UAREP that those twelve studies, as well as the
three that were reviewed by the FDA were authentic.43
Former FDA ocial, M. Adrian Gross, a veterinarian and pathologist, led the
task force set up by the FDA in July of 1975 to investigate the validity of Searle
animal studies on aspartame and Aldactone. Aldactone was a widely prescribed
drug for high a blood pressure and the only aforementioned Searle product that
was eventually examined by the grand jury. Although the task force eventually
concluded that the studies provided valid conclusions with regard to the safety
of aspartame, the analysis of these studies was not an easy task and the results
were not entirely clear.
VII. Analyzing the Data: The 52-Week Toxicity Study in the
Infant Monkey
In 1969 Searle commenced a study of the side eects of aspartame as com-
42Id.
4346 Fed. Reg. 38285 at 38286
15pared with those of phenylalanine. Searle chose Dr. Harry A. Waisman, a
leading researcher associated with the University of Wisconsin Regional Pri-
mate Center who had published extensively on the toxicity of phenylalanine, to
lead the research eort. Dr. Waisman's earlier writings established that pheny-
lalanine is capable of producing brain damage in Rhesus monkeys.44 Although
Dr. Waisman seemed to be quite capable of completing the proposed research,
things did not turn out as expected. The study was initiated on January 15,
1971. Unfortunately, Dr. Waisman died a little over a year after the experi-
ments began. The study was terminated about a month later on or about April
25, 1971. Searle then submitted its report to the FDA on October 10, 1972.
Analysis seems to indicate that the results of the study were falsely deemed
conclusive when in reality, many questions remained.
The study included seven newborn Rhesus monkeys who were fed a diet that
included aspartame. The study did not have a control group of newborn mon-
keys who were not fed aspartame. According to a Searle document that was
drafted after the initiation of the study, the monkeys were to be kept on a diet
with aspartame for one year before being returned to a basal diet. They were
then to be subjected to behavioral and learning tests; and nally sacriced and
necropsied for the preparation of tissue slides to be reviewed microscopically
for alteration.45 Of the seven test monkeys, one died after 300 days; four were
continually fed a diet containing aspartame for 365 days as planned; and ad-
ministration of aspartame for two others was ceased after 200 days. According
44Supra note 35
45Id.
16to the records, no behavioral or learning tests were performed. Only the one
monkey that died during the test was necropsied. It is clear that the test results
are not conclusive as to the side eects of aspartame. Searle has since referred to
the study as a pilot experiment, and acknowledged its evident shortcomings.46
Despite Searle's subsequent disparagement of the study, according to the De-
partment of Health, Education and Welfare, the company provided this inade-
quate study to the FDA in order to expedite the approval of aspartame. The
Department's memoranda states that [t]he report to FDA is drafted in a manner
which covers up the admitted inadequacy of the design, control and documen-
tation of the study. However, when Searle is accused or (sic) representing this
study for far more than it was (sic), it denies almost all knowledge of or involve-
ment with its initiation, design or performance... 47 The Department goes on
to accuse Searle of many deviations from standard research practice. The accu-
sations include concealing the fact that the infant monkeys were not suitable for
the study, and falsely stating that the necropsy data on the one non-surviving
monkey was lost do to similar reasons, namely confusion after Dr. Waisman's
death.48 Whether or not these allegations proved to be true is unclear. It is
quite apparent, however, that by the accounts of all parties, the study was in
many ways inadequate and incomplete.
VIII. Analyzing the Data: the 46-Week Hamster Study
Another study that engendered severe criticism from the Department of
46Id.
47Id.
48Id.
17Health Education and Welfare (the Department) was the 46- week toxicity
study performed on the hamster. Although the data appears to be faulty and
incomplete, Searle argues that any falsehood in the study is not material to the
appraisal of the safety of aspartame.49
The Department's report provides a chronology of the numerous problems they
allege that the study encountered. It seems that many of these contentions
are uncontested by Searle though the company does not agree that the data is
therefore useless. The hamster study was intended to be a 104 -week toxicity
study on aspartame in the hamster. Unfortunately, the study was terminated
after 46 weeks due to a high mortality rate in both control and treated animals
that was not ascribed to aspartame.
In addition to criticizing the study as a whole, the Department alleges that
Searle violated Title 18, Section 1001by falsifying data. The report alleges that
the testing ran into problems and instead of correcting them, Searle covered the
problem up. Blood from certain animals in the study was collected for hema-
tology testing and blood chemistry at the scheduled 26 - week interval. At that
time, samples were drawn and the appropriate testing was performed. The test-
ing included six dierent tests. Out of the six, the results for the serum glucose
(blood sugar) appear problematic. Apparently the technicians had method-
ological problems with that test. According to the Department, Searle did not
correct this problem until about 12 weeks later and by that time approximately
30 percent of the hamsters had died.50
49Id. at 173
50Id.
18At the 38th week of the study, other hamsters were taken as substitutes from
the same feeding groups and blood was collected from them. According to the
Department, Searle substituted the glucose values of the new animals' blood as
being those of tests run at 26 weeks on blood samples from the original animals.
Hence, the Department concluded that glucose values presented in the study
that were supposed to represent one set of animals really represented another.51
Subsequently, Searle has admitted that the report contains this false informa-
tion, but argues that the inclusion of false data did not result from willful con-
duct or any intentional act. Furthermore, Searle has argued that this inaccuracy
is not material to the appraisal of the safety of aspartame and that there was no
motive for any intentional misrepresentation regarding the glucose values of the
hamsters.52 It appears that the question of glucose levels was non-controversial
with regard to the results of the study. Even the Department has acknowledged
that the substituted data may not have been material to a determination of the
ultimate safety of aspartame.53
IX. Task Force's Conclusions
After analyzing the data and conclusions of Searle's aspartame and Aldac-
tone studies, the task force concluded that the data was inconclusive and more
research was necessary. Adrian Gross, former FDA investigator and scientist,
presented the comments of the task force. In his statement, Gross noted that
the conclusions of the task force in fact represented an FDA institutional view
51Id.
52Id.
53Id. at 174.
19which Commissioner Schmidt had agreed upon in 1976.54 The comments made
by Gross regarding the task force's conclusions centered around three main top-
ics as articulated by Gross:
(a) The studies carried out by Searle to establish the safety of aspartame;
this is a conclusion that would follow the FDA's own extensive investigations
into the acceptability of experimental studies conducted by and for Searle...
(b) Their serious shortcomings notwithstanding, at least on of those studies
has established beyond any reasonable doubt that aspartame is capable of in-
ducing rain tumors in experimental animals and that this predisposition of it is
of extremely high signicance...
(c) I would view the Acceptable Daily Intake (ADI) set by the FDA for
aspartame (5mgm/kgm body weight/day) as totally unwarranted and extremely
high in that it can be associated with completely unacceptable risks as far as
the induction of such tumors are concerned... 55
In conclusion, Gross, in his statement on behalf of he task force said, At the
heart of FDA's regulatory process is its ability to rely upon the basic safety data
submitted by sponsors of regulated products. Our investigation clearly demon-
strates that, in the G. D. Searle Co., we have no basis for such reliance now.56
Furthermore, Gross later stated that Searle's own studies established beyond a
reasonable doubt that aspartame is capable of inducing brain tumors in experi-
mental animals.57 In July of 1975, even the FDA Commissioner concluded that
the integrity of certain animal studies conducted by Searle were questionable.58
Though it did not necessarily implicate the safety of aspartame as a food
additive, the task force's audit renewed concern about the additive's safety. On
January 10, 1977, the Department of Health, Education and Welfare submitted a
54Id at 180.
55Id.
56Wash. Post., Feb. 7, 1986, B9
57Id.
58Id.
20detailed request to Samuel K. Skinner, U.S. Attorney for the Northern District
of Illinois for a Grand Jury investigation. The Department urged Skinner to
convene a Grand jury investigation based on apparent violation of the Federal
Food, Drug, and Cosmetic Act, 21 U.S.C. 331(e), and the False Reports to the
Government Act, 18 U.S.C. 1001 by G. D. Searle and Company, including three
of its responsible ocers. The request alleged that these parties willfully and
knowingly failed to make reports to the Food and Drug Administration required
by the Act, 21 U. S. C. 355(I). Furthermore, it alleged that Searle concealed
material facts and made false statements in reports of animal studies conducted
to establish the safety of the drug Aldactone and the food additive Aspartame.59
X. Senator Metzenbaum's 1977 Report
Prior to the request for an investigation into the actions of Searle and its top
ocers, Senator Metzenbaum's sta had produced an extensive and somewhat
similar request for further investigation of Searle and the safety of aspartame.
In raising questions about the clinical methods that Searle employed to verify
the safety of aspartame as a food additive, however, the report gets mired in
accusations of fraud. The authors seem to lose sight of the important question
of whether aspartame is indeed safe for human consumption. The report focuses
on Searle's strategies with regard to marketing and seeking approval from the
FDA instead of true safety concerns. For example, in discussing two of Searle's
clinical studies, the 46-week toxicity study in the hamster and the 52-week
toxicity study in the infant monkey, the report states:
59131 Cong. Rec. S10800-01
21In considering the extent to which the reports [of the monkey and hamster
studies] were written to convey impressions more favorable than the underlying
data would support, reference should be make to the memorandum of December
28, 1970, from Mr. Helling of Searle to, among others, Drs. | [omitted in
original], entitled Food and Drug Sweetener Strategy. In that memorandum,
Searle commits itself to obtaining favorable review by FDA personnel by seeking
to develop in them a subconscious spirit of participation in the Searle studies.60
Although interesting, and possibly even relevant as to the moral character
of Searle employees and company strategy, it is not of great importance with
regard to the safety of aspartame.
XI. The Board's Inquiry
In response to Senator Metzenbaum's report and the request of the task
force, in June of 1979, FDA announced a hearing and set up a public board of
inquiry to look into the safety of aspartame as a food additive.61 The board,
which had been set up previously by FDA with the suggestions of Dr. John
Olney, Searle, and the Bureau of foods, was to look into several issues, including:
1. Whether the ingestion of aspartame, whether alone or together with
glutamate, poses a risk of contributing to mental retardation, brain damage, or
undesirable eects on neuroendocrine regulatory systems.
2. Whether the ingestion of aspartame may induce brain neoplasms (tumors)
in the rat, and
3. Based on the answers to the above questions, (a) should aspartame be
allowed for use in foods, or instead should the approval of aspartame be with-
drawn? (b) If aspartame is allowed for use in foods, i.e., if its approval is not
60Id. at 174.
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22withdrawn, what conditions of use and labeling and label statements should be
required, if any?62
The notice species that the board's decision regarding these issues would
become nal unless the parties led exceptions.63 If exceptions were led, the
commissioner was to review the decision and make his own determinations.64
The board had its rst meetings on January 30, 31 and February 1, 1980.65
On the rst question, whether the ingestion of aspartame poses a risk of con-
tributing to mental retardation, brain damage, or undesirable eects on the
neuroendocrine regulatory system, the board found that aspartame did not
pose an increased risk of brain or endocrine dysfunction.66
On the second issue, however, the board ruled that aspartame might cause can-
cer.67 In response to the multifaceted third issue, the board vacated the stay on
the aspartame regulation and revoked the regulation. The board had concluded
that aspartame should not be on the market until further safety testing had
ruled out potentially dangerous side eects.68
The board's consideration had a decidedly narrow scope. It included only three
studies dealing with aspartame's propensity to cause tumor formation. The
reason for this was that these were the only relevant studies that Searle re-
ported.69 Out of the three studies the board reviewed, two were found to be
62Final Decision, supra note 13, at 38,737; 46 Fed. Reg. 38,286.
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66Initial Decision, supra note 13 a 38,346.
67Id. at 38,349.
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69Id. at 38,346.
23problematic. The rst study raised questions because it indicated a high rate
of death amongst young test rats and a possible dose-eect relationship that
indicated aspartame may cause cancer.70 The second study troubled the board
for several reasons. First of all, it used an apparently insucient number of
experimental animals. And secondly, the control group had a higher incidence
of brain tumors than the board though normal.71
In conclusion, the board determined that it was dicult, if not impossible, to
judge aspartame's possible oncogenity on the basis of the data provided by
Searle.72 The board acknowledged that the results of the study might have
been misleading because the test animals were fed enough aspartame to cause
amino acid imbalance. Therefore the study could have produced results that
would not have been reproduced as a symptom of human intake of aspartame.
However, the board decided that on the record before it, an oncogenic eect
from aspartame could not be ruled out entirely.73
Surprisingly, the FDA commissioner only diered signicantly on the evidence
pertaining to carcinogenicity.74 He took issue with the way the board evaluated
the data for the two aforementioned studies, however.75 In the rst study he
found that the board had made an error in their calculation of the statistical
analysis,76 and had made factual errors in noting age at death for certain lab
rats.77 The commissioner noted that when the errors were corrected, the study
70Id. at 38,347.
71Id. at 38,348.
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74Final Decision, supra note 13, at 38,752-64; 46 Fed. Reg. 38,294-301.
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24was found not to indicate carcinogenicity.78 In the second study, the commis-
sioner found that the board had set a normal rate of tumor incidence much too
low,79 thereby incorrectly dismissing concern over the study size.80
XII. The Commissioner's Reversal
The board's decision against aspartame approval and its call for more safety
testing elicited numerous protests. All parties led exceptions.81 Since ex-
ceptions were led, the Commissioner had the responsibility of reviewing the
ndings and making a decision that could contradict the task forces' conclusions.
Searle immediately took further action by issuing press releases contesting the
board's determinations.82
On July 24, 1981, FDA Commissioner, Arthur Hull Hayes Jr. ruled that
the sweetener, aspartame, is safe.83 Despite the board's nding Commissioner
Hayes approved the additive's use in food. The FDA granted broad approval
for aspartame's use as a tabletop sugar substitute, as a tablet or as an additive
in cereals, drink mixes, instant coee and tea, gelatins, puddings, llings, dairy
products and toppings.84 However, it was not approved for use in soft drinks
at that time because Searle had not sought such approval.
78Id. at 38,764; 46 Fed. Reg. 38,301.
79Id at 38,758; 46 Fed. Reg. 38,298.
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25In discussion of his decision to overrule the board that urged long-term study
to make sure that aspartame did not cause brain tumors, the Commissioner
noted what he believed to be errors that the board made in their inquiry which
led them to conclude that more research was necessary. Commissioner Hayes
also cited a study by Ajinomoto Co., Inc., the Japanese licensee of Searle's as-
partame patent that armed aspartame's safety. The study was released after
the board had published its decision against aspartame approval. Hayes jus-
tied including the study in his consideration of the evidence despite its late
availability by noting that the proceeding was intended to be a scientic inquiry
using all available evidence.85
One safety concern that FDA did address further was the issue of aspartame
consumption by persons with the hereditary disease phenylketonuria or PKU.
Individuals with PKU must avoid protein foods that contain phenylalanine,
one of aspartame's principle components. Accordingly, FDA established a re-
quirement that food makers put a warning label on packages of food containing
aspartame to give notice to those with PKU. FDA also planned to require man-
ufacturers to monitor aspartame consumption levels.86 This safety requirement
was present in the original regulation authorizing aspartame to be used as a
sweetener in foods.87
XIII. FDA Continues Approving Aspartame for Additional Uses
Despite Pressure from Consumer Groups
Once aspartame had been ocially sanctioned for use as a sweetener in a
85Final Decision, supra note 13, at 38,753-54; 46 Fed. Reg. 38,295.
8646 Fed. Reg. 3828; 46 Fed. Reg. 50947.
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26limited number of foods, Searle began ling additional petitions for approval
and the FDA responded by granting them despite the controversy that still sur-
rounded aspartame. In 1983 the FDA proposed to declare aspartame suitable
for use as an inactive ingredient in human drug products provided that the label
and labeling of the drug products declared the presence and amount of the com-
ponent phenylalanine that was contained in the drug product per dose unit.88
The FDA made this proposal in response to inquiries from drug manufactur-
ers. In 1987, the FDA issued a nal rule declaring that aspartame, when used
at a level no higher than reasonably required to perform its intended technical
function, is safe for use as an inactive ingredient in human drug products.89
XIV. The Approval Process Continues and the Soft-Drink In-
dustry Adjusts
Although aspartame would eventually prove to be a catalyst for major in-
creases in diet soft-drink sales, at the time of its approval, the soft-drink industry
was resistant to making the change from saccharine, which had been the dom-
inant non-sugar sweetener, to the newer aspartame.90 Ironically, the industry
that has arguably beneted the most from the aspartame tried to convince the
FDA to delay its use in diet sodas.91 In the early eighties, after aspartame had
been approved for use in food and pending its approval for soft drink use, the
National Soft Drink Association (NSDA), which at the time represented the na-
tion's major soft drink makers, raised health and quality control concerns about
8848 Fed. Reg. 54993
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90Wash Post, July 14, 1983, at A1
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27the sweetener.92 The NSDA wrote a letter to the FDA requesting the delay
of aspartame's approval. The letter expressed the industry's doubts about as-
partame's ability to keep its sweetness in high temperatures and over extended
periods of time.93
Industry sources and analysts saw dierent reasons for the NSDA objections.
Some said that the industry was not nancially prepared for the change and that
the NSDA wanted to stall the FDA approval until there would be less risk of
economic upheaval. Others speculated that the two major soft drink companies,
Coca-Cola Co. and PepsiCo Inc., were afraid that rival 7-Up would use the new
sweetener to its advantage in extending its successful no-articial-ingredients,
no-caeine campaign before they were ready to put forth competing products.94
There was also speculation that the industry wanted to postpone the approval
of aspartame until the market-mayhem caused by the introduction of Diet Coke
and numerous other caeine-free soft drinks had settled down.95
Meanwhile, the same soft drink makers were scrambling to buy large quan-
tities of aspartame in case its approval could not be delayed.96 Since the sweet-
ener was still in relatively short supply and only manufactured by Searle, a
fear-driven competition for the additive began. Coca-Cola Co. and PepsiCo
Inc. were apparently afraid that 7-Up would corner the aspartame-sweetened
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28soft drink market unless Searle had produced enough aspartame to satisfy the
demand.97 Robert Shapiro, the then head of the Searle division that made
aspartame for commercial use, stated that in his discussions with soft-drink
companies there had been no reluctance on their part to put aspartame into
their diet soft drinks. There had been anything but that, he said.98 It seems
likely that while none of the soft-drink companies wanted to be left behind if
aspartame were to be a market hit, they were concerned about the trouble it
could bring in light of the history of cyclamates and saccharin.
XV. Aspartame's Market Share of the Low Calorie Sweetener
Industry Explodes
As predicted, the FDA approved aspartame for use in soft drinks in July
of 1983.99 In response to soft-drink industry's safety concerns, FDA said that
it was satised that aspartame would not cause quality-control problems for
soft-drink makers or health problems for users. According to one FDA ocial,
aspartame was, at that time, the most extensively tested food additive FDA
had ever approved.100
Aspartame's initial introduction to the market in the United States came in
1981; in 1984, the year after aspartame was approved for use in soft drinks,
Searle sold $600 million worth of aspartame, on which it held the exclusive
United States Patent.101 Searle began using the trade names Equal and Nu-
traSweet to market the product. Coca-Cola's consumer poling indicated that a
97Id.
98Id.
9948 Fed. Reg. 31376
100Wash Post, July 14, 1983, at A1
101NY TIMES, July 3, 1985, A Sweetener's Eects: New Questions Raised by Marian Burros
29signicant number of diet soda drinkers and infrequent soda drinkers would be
attracted to Coke's new product, Diet Coke with NutraSweet. This data turned
out to be accurate as aspartame-sweetened Diet Coke became increasingly pop-
ular.102 In addition to its wide consumer appeal, aspartame also received a
positive response from government ocials. Dr. Richard Ronk, then deputy
director of the Bureau of Foods for the Food and Drug Administration called
it [T]he ideal food additive, noting that aspartame has one-tenth of a calorie
in the amount needed to replace one teaspoon of sugar (18 calories), does not
cause cavities, and is supposedly safer than saccharine.103
XVI. Searle's Business (as Aected by the Market for Aspar-
tame)
As market demand for aspartame grew, Searle had an increased need for the
ingredients that make up the additive. In order to quickly and eciently meet
the demand, Searle had to adjust its business plan. Instead of continuing to
rely on the Japanese supplier of L-Phenylalanine, one of the key components of
aspartame, Searle ocials began looking for new ways to obtain it. They also
sought new ways to obtain L-asparatic acid, the amino acid that is mixed with
L-Phenylalanine in roughly equal portions to produce aspartame. Searle sought
a manufacturer of the ingredients that could avoid the relatively expensive fer-
menting process used by the Japanese company to create L-Phenylalanine.
In August of 1983, Searle entered into a contract with Genex Corp., a biotechnol-
ogy company, to buy L-Phenylalanine produced through a new method. Genex
102Wash Post, August 28, 1983, at M1
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30asserted that through an innovative bio-reactor technology, the company would
be able to produce the chemical faster and at a lower cost than it had been
produced in the past.104 The agreement also granted Searle a license and rights
of access to some areas of Genex technology that involved sweeteners other than
aspartame.105 It seemed that the contract would provide both companies with
opportunities that they had eagerly sought out.
In 1993, NutraSweet accounted for 35 percent of Searle's sales. Projections for
1984 indicated that NutraSweet sales would provide 50 to 55 percent of total
sales.106 It was the middle of 1984 when the heirs of the founder of G. D. Searle
& Co. decided that it would be in their best interests to diversify their holdings;
even if this proposition would lead to the sale of the company.107 In a statement
for the press, the family members, who include Daniel Searle, William Searle,
and Suzanne Dixon, said that they have been delighted at the progress that
the company has made in recent years and recognize the potential for very sub-
stantial growth in the future. But they added that having such a large portion
of the family's nancial interests tied up in one enterprise prompted them to
consider diversication.108 It is unclear whether this sudden desire for diversi-
cation reected concern over the fate of NutraSweet, or just cautious nancial
planning. Despite the phenomenal reported earnings of $151.2 million in 1983,
the NutraSweet controversy was far from over.109
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31In June of 1985, Searle made headlines once more, though not directly on ac-
count of aspartame. In its search for corporate eciency, Searle executives
decided not to renew its contract with Genex Corp., the company that had pro-
duced a component of aspartame for Searle. At Genex's annual shareholder's
meeting, which took place on October 31, Genex Chairman J. Leslie Glick an-
nounced that Searle was planning to let Genex's contract expire that year.
The visceral reaction Genex had was due in part to its heavy investment in a
manufacturing plant to produce the aspartame component, L-Phenylalanine in
accordance with the Searle contract.
Although Genex spokeswoman, Shellie Roth said that Searle's decision was not
a life-threatening blow, Genex's only other commercial product was an enzyme-
based drain cleaner which, according to the company, produced negligible sales
in 1984.110 Furthermore, Genex had seen its revenue and losses both swell in
1984 with the success of its aspartame ingredient and the costs of starting up
a manufacturing plant for the ingredient. The company's revenue tripled com-
pared with the prior year, but reported losses increased to $7.4 million in 1984
from $5.4 million in 1983 due largely to start up costs of the manufacturing
plant.111 Searle provided little public response to Genex's complaints about the
contract expiration.
Within a year, Genex had taken action against Searle by ling a $40 million
suit alleging fraud, concealment and violations of federal securities, anti-trust
and anti-racketeering laws. Though Searle remained mute in the press, its rep-
110Wash Post, June 14, 1985, at F1
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32utation again took a beating. The plaintis argued that Genex should be paid
$40 million in actual damages, in addition to punitive damages at least equal
to the actual damages and treble damages because of violations of anti-trust
and other federal laws.112 Genex alleged that Searle's refusal to renew Genex's
contract had a devastating impact on Genex after Genex had invested approxi-
mately $17.5 million in a new manufacturing plant designed for the production
of L-Phenylalanine, a product Genex produced for Searle.113 The lawsuit also
alleged that Searle made material and false representations leading Genex to be-
lieve that Searle wanted a long-term supply relationship, and thereby induced
Genex into dramatically increasing its production capabilities.114
Although the Genex suit was eventually settled out of court, Searle's reputa-
tion took another blow in the news. It is likely that Searle's negative reputation
contributed in some way to consumer fears of aspartame. Despite reports that in
the settlement, Searle only paid Genex a nominal amount, and Searle dropped
a claim that Genex overcharged it $1.35 million, Searle's payment signaled an
acceptance of wrongdoing.115 It is dicult to tell what consumer reaction to
this settlement was; it is doubtful that there was great consumer interest, but
the settlement contributed in some way to Searle's increasingly dim reputation
amongst consumers.
XVII. Senator Metzenbaum's 1985 Bill
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33The ongoing controversy surrounding Searle and the manufacture and sale
of aspartame is apparent in a bill introduced in Congress in 1985. Senator
Metzenbaum, a long time opponent to aspartame's approval, introduced a bill
called the Aspartame Safety Act of 1985.116 This bill was intended to provide
consumers with information concerning the use of products containing aspar-
tame, to provide for the conduct of studies to determine the health eects of
using products containing aspartame, and for other purposes. In his address
to Congress, Senator Metzenbaum stated that this bill contained the absolute
minimum that Congress needs to do in order to protect the health and safety
of the 100 million American consumers who are using this chemical sweetener
under its better-known brand name of NutraSweet.117
Senator Metzenbaum's concerns seem to stem from what he referred to as the
troubling circumstances under which the FDA approved aspartame.118 That
issue was in his mind exacerbated by the quantity of the product being con-
sumed. The Senator noted that in 1984, Americans consumed over 7 million
pounds of aspartame, which is equivalent to 1.4 billion pounds of sugar. He
went on to predict that in 1985 Americans would consume over 20 billion cans
of diet soft drinks, the vast majority of which are sweetened with 100 percent
NutraSweet.119 Despite the dubious accuracy of these statistics, it is clear that
Senator Metzenbaum's desire to nd answers to any safety questions about as-
partame was echoed by a large number of American consumers.
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34Senator Metzenbaum's bill centered on the problematic nature of Searle's re-
search methods and the nature of the FDA, which he called a mere shadow of
what that agency used to be.120 His doubt about the accuracy of the aspar-
tame safety tests and the ability of the FDA to suciently judge the safety of
aspartame are highly apparent, but he does not provide any factual basis for
doubt of the FDA's decision to approve the product. In fact, it seems that he
is advocating the same kind of review of the tests that had already occurred by
that time.
Just one year prior to the introduction of the Aspartame Safety Act of 1985, the
federal Center for Disease Control (CDC) had completed a review of aspartame.
After nishing the review, researchers concluded that there was no evidence of
serious, widespread adverse health consequences among those who consumed
the sweetener in diet soft drinks and other products.121 The four-month long
study included approximately 600 participants. It looked at complaints noted by
consumers, many of whom reported more than one symptom. Two-thirds of the
complaints involved nervous system or behavioral problems such as headaches,
dizziness, and mood changes. One-fourth of the complaints reported included
gastrointestinal symptoms, and 15 percent reported included allergic-type reac-
tions.122
The CDC scientists concluded that there was no particular pattern in the re-
ported symptoms. The analysis of nearly 600 complaints from people who con-
sumed aspartame demonstrated that a wide variety of complaints... [were] gen-
120Id.
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35erally of a mild nature.123 The CDC review noted that most of the symptoms
were so common that it was impossible to tell whether the complaints were
unrelated to the sweetener or resulted, at least in part, from some individuals'
unusual sensitivity to the product.124
The CDC's conclusions should have provided consumers with some re-assurance,
but if they did, it was not widespread. Complaints of aspartame-related illness
continued along with the controversy. In a letter to then FDA Commissioner,
Frank Young, Community Nutrition Institute criticized the FDA and the CDC's
report on aspartame.125 The letter alleged that no serious eort had been made
to determine the actual extent of consumer reactions to NutraSweet, or to ana-
lyze and categorize the complaints.126 It also accused the FDA of not inviting
physicians to send in reports of complaints and therefore making it easy for
FDA to claim that the complaints about aspartame could be explained by the
placebo eect. The placebo theory being that whenever any new product is
introduced, the public seizes upon it as the source of their ailment.
Within a year of publication of the CDC's report, Senator Metzenbaum's bill,
the Aspartame Safety Act of 1985, was discussed in the Senate. The bill included
a number of mandates that the Senator felt would increase the likelihood that
aspartame was being used safely. In addition to additional independent testing
of aspartame, the bill required product labels with specic amounts of aspar-
tame per serving products contained. This was intended to inform consumers
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36how much aspartame they were consuming. This requirement was also intended
for physicians who were treating individuals who felt that they had aspartame-
related side eects since such side eects were thought to be dose related.
The proposed labeling requirements also included a statement regarding the
maximum allowable daily intake established by the FDA. There was also a
required advisory statement on the label that would inform consumers that as-
partame is not intended for infant feeding.127 Finally, Senator Metzenbaum's
bill proposed to establish a Clinical Adverse Reaction Committee within the
FDA. This committee was intended to address the problems of consumers who
felt that they had experienced negative eects from aspartame and investigate
their claims.128 Despite the passionate attempt on the part of Senator Met-
zenbaum and a group of consumer advocates, the bill never became law; the
controversy surrounding aspartame did not diminish.
XVIII. Community Nutrition Institute Files Suit
In fact, the controversy was again heating up. On the day that Senator Metzen-
baum introduced the Aspartame Safety Act of 1985, a national organization,
known as the Aspartame Victims and Their Friends, Inc. was launched at
a Washington, D.C. press conference. The organization, which was aliated
with the Aspartame Resource Center of the Community Nutrition Institute, a
Washington-based consumer group, set up headquarters in Ocala, Florida. At
that press conference one of the founding members of the group announced that
127Supra note 115 at 137.
128Id.
37a lawsuit would be led against Searle with regard to the manufacture of as-
partame. The group also announced that it would operate a national telephone
hotline for victims of bad reactions to aspartame.129 The Executive Director
of the Community Nutrition Institute, Ron Leonard, said that the new orga-
nization would provide a link between aspartame users who have experienced
adverse reactions and have suered injury and economic loss.130
On December 23, 1983, Community Nutrition Institute (CNI) led a complaint
requesting that the Court enter an order directing the FDA to conduct public
hearings to determine the safety of using the food additive aspartame in car-
bonated beverages.131 CNI's complaint also sought an order staying the FDA's
regulation permitting the addition of aspartame to carbonated beverages until
such time as the FDA would convene and conclude the requested public hear-
ings. On August 8, 1983, the plaintis had previously led with the FDA similar
requests for a hearing and a stay, along with objections on the merits to the
approval of aspartame's use in carbonated beverages.
On January 24, 1984, CNI led a motion for a temporary restraining order seek-
ing relief on an emergency basis. The group also sought to broaden their request
for a temporary stay to bar the addition of aspartame not only to carbonated
beverages, but to all food products. The District Court denied CNI's motion
for a temporary restraining order. In an Order entered on January 27, 1984,
the Court noted several deciencies with the group's motion. According to the
Court, the adavits submitted by CNI in support of the motion were largely
129Id. at 197.
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38anecdotal, the conclusions advanced were unsubstantiated by direct scientic
evidence and most of the factual assertions relied upon were in actuality inad-
missible hearsay. The Court also noted in the order that the government had
indicated, at the argument on the motion for a temporary restraining order, that
a FDA ruling on the plainti's request for a public hearing was imminent.132
On February 15, 1984, CNI led a second motion for a temporary restraining or-
der. Two days later, the FDA entered a nal ruling on plainti's request for an
oral hearing. Not surprisingly, the FDA denied CNI's request for a hearing.133
Furthermore, in response to CNI's second motion for temporary injunctive re-
lief, the FDA led a motion to dismiss. In this motion, FDA asserted that the
District Court lacked jurisdiction to make a determination on the matter and
that judicial review was appropriate only in the court of appeals.134
On March 22, 1984 the United States District Court, in D. C. heard the case
Community Nutrition Institute, et al., v. Dr. Mark Novitch, Acting Commissioner Food and Drug Administration.135
District Judge Barrington D. Parker, writing for the District Court, held that
under section of the Food, Drug, and Cosmetic Act governing judicial review of
FDA orders relating to food additives, jurisdiction over FDA orders pertaining
to aspartame lay in Court of Appeals, not district court. The Court determined
that FDA's motion to dismiss should be granted and CNI's motion for a tem-
porary restraining order should be denied.136
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39The plaintis appealed, and on January 25, 1985 Community Nutrition Institute, et al., v. Dr. Frank Young, Commissioner, Food and Drug Administration
began.137 The case was heard before a panel of three Circuit judges: Judge
Mikva, Judge Edwards and Judge Starr. The underlying issue in that case, as
the judges interpreted it, was the FDA's action in approving the use of aspar-
tame in liquids. The judges therefore, reviewed the FDA's regulation approving
the use of aspartame in liquids and the District Court's dismissal of a claim
seeking to compel the FDA to conduct a hearing on aspartame, as well as a
request to stay the approval pending the hearing, for lack of jurisdiction.138
Circuit Judge Abner Mikva, writing for the Court of Appeals, held that the
district court lacked jurisdiction over the request for a stay of eective date
of rules approving both wet and dry use of the articial sweetener aspartame.
The opinion notes that the exclusive grant of jurisdiction to the Court of Ap-
peals meant that mandamus to obtain a stay was available only in the Court
of Appeals. Secondly, the Court held that the FDA did not exceed its lawful
discretion in denying requests for a hearing on possible dangers of aspartame
in carbonated soft drinks and other wet uses. The Court's conclusion rested on
the fact that the parties requesting a hearing failed to raise any material issue
regarding the safety of wet use of aspartame.139
XIX. FDA Invites Consumer Participation
Before the Court of Appeals ruled in the case, Community Nutrition Institute v. Young,
the FDA decided to invite consumer participation in an open meeting address-
137773 F.2d 1356, 249 U.S. App. D.C. 150
138Id at 1357-58.
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40ing aspartame, amongst other things. On October 3, 1984 the FDA announced
this meeting which was chaired by Jack Dempster, Director of Compliance.140
This meeting came as a surprise since the FDA's recent denials of requests for
a hearing on aspartame safety issues had spawned the aforementioned litiga-
tion. This new invitation for consumer participation in an open meeting can
be interpreted as a means of allaying consumer fears about the product. How-
ever, unlike the hearing that was initially requested, this open meeting was not
set up to address safety issues related to the amendment to the food additive
regulation concerning aspartame. That regulation is the one that provides for
the safe use of the substance in carbonated beverages and carbonated beverage
syrup bases. Consumer advocates were further thwarted by the fact that this
meeting was scheduled to be only an hour long, and it took place in Detroit,
MI.141
XX. The General Accounting Oce's Report
Despite the Court's ruling in Community Nutrition Institute v. Young, oppo-
nents of aspartame continued their mission to ban the food additive. As per
Senator Metzenbaum's request made in 1985, the General Accounting Oce,
(GAO) undertook a comprehensive study regarding whether the FDA followed
proper procedures in approving the sale of aspartame and whether the FDA
was conducting adequate follow up studies to monitor the safety of the prod-
uct. On July 16, 1987, the GAO released its completed report. The GAO
concluded that the FDA had indeed followed proper procedures in its approval
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41of aspartame as well as its continuing eorts to monitor the safety of the popu-
lar sugar-substitute.142 Throughout aspartame's approval history, GAO found
that FDA addressed safety issues raised internally and by outside scientists and
concerned citizens, the report stated.143
Despite the assurance of this respected body, who polled 69 medical researchers
regarding their condence in the safety of aspartame, some consumers concerns
were not obviated. Because it had no medical expertise, the GAO made no rec-
ommendations in its report. The group found that the FDA adhered to proper
procedures by approving the sweetener, but the GAO investigators said that
they could not comment on whether important issues surrounding aspartame's
safety remain unresolved.144 One critic of the report, Dr. Louis Elsas, direc-
tor of medical genetics at Emory University Medical School commented, They
never asked the right questions about what [aspartame] does to brain function
in humans. He continued, They decided without data that you had to have
enormous amounts of phenylalanine in your blood before it becomes a problem.
We don' t know that's the case (sic).145 Furthermore, Senator Metzenbaum,
an outspoken opponent to the approval of aspartame for use in food, said in a
statement that more than half the researchers surveyed by the GAO said they
had some concerns over safety.146 The Senator, who was at the time chairman
of the Labor subcommittee of the Labor and Human Resources Committee, said
that he would convene a hearing of his subcommittee in September to consider,
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42once again, the safety of aspartame.147
Prior to Senator Metzenbaum's 1987 request for a GAO report, Senator Gaylord
Nelson made a similar request for investigation in 1975.148 In response to Sena-
tor Nelson's request, the GAO undertook a detailed analysis of three additives:
Food, Drug, and Cosmetic Red No. 2; saccharine; and aspartame for use in
food. The purpose of the rst GAO investigation into aspartame for use in food
focused on several general goals. First, the report was to look at the history of
FDA's regulation of aspartame, including in-house and outside tests leading to
change in regulated status. Second, the GAO was charged with investigating the
current status of testing of aspartame and FDA activities aecting the status of
aspartame. Thirdly, the report was to determine the extent to which FDA had
examined alternatives to aspartame since its safety was questioned. Finally, the
report was to examine whether based on the scientic evidence available, the
regulatory action taken by the FDA on aspartame complied with the Federal
Food, Drug, and Cosmetic Act, as amended.149
In the process of undertaking this investigation, the GAO reported that it
concentrated on the period since 1973, when a petition for aspartame's use was
submitted to FDA for approval. The Oce reviewed pertinent legislation, reg-
ulations, and practices relating to FDA's regulation of food additives; examined
FDA records relating to the regulatory status of aspartame; and reviewed docu-
ments submitted by its petitioner in support of the additive's safety. The GAO
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43also purportedly interviewed ocials of FDA; Canada's Food and Drug Direc-
torate, Ottawa, Canada; and Searle ocials. After completing the investigation
in 1976, the GAO concluded that the FDA had followed proper procedures in
approving the sale of aspartame and was conducting adequate follow up studies
to monitor the safety of the product.150
The GAO's subsequent report on the safety of aspartame which was released
over ten years later, in 1987, was similarly unsuccessful in allaying the fears of
many consumer advocates and quieting the controversy that aspartame had
stirred up. Although the GAO's report carried a signicant amount of weight
within the government and the legal community, the text of the report on as-
partame did not add much additional information to what was already public
knowledge. Because the GAO does not have any medical expertise, its role in
this situation was limited to determining whether the FDA acted within the
bounds of the law, and polling medical researchers for their thoughts on the
safety of aspartame.
The GAO report did not discover much in terms of new data; its focus was on
reviewing the FDA's process in approving aspartame. In determining whether
a proposed use of a food additive is safe, the Food, Drug and Cosmetic Act
requires FDA to consider several things:
1) The probable consumption of the additive and of any substance formed
in or on food through use of the additive.
2) The cumulative eects of the additive in the diet of man or animals,
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substances in the diet; and
3) Safety factors generally recognized by qualied experts as appropriate for
the use of animal experimentation data.151
The statute mandates that a food additive will be deemed unsafe and re-
stricted from public use by FDA if available information fails to establish the
safety of its proposed use or if it is found to induce cancer when ingested by
man or animals.152 The GAO reviewed the FDA's data and concluded that
there was no wrongdoing, but because of the somewhat vague nature of these
factors, it is easy to see why persistent fears of some anti-aspartame consumer
rights groups remained. Even the opinions of the medical researchers who par-
ticipated in the poll were varied enough to feed ongoing controversy despite the
reassuring nature of the GAO's conclusions.
It is interesting to note, however, that both sides of the aspartame struggle
claimed that the GAO report supported their beliefs about the safety, or lack
thereof, of aspartame as a food additive. This was possible because the poll
results were mixed. Although the majority of the sixty-seven participants who
responded to the question regarding aspartame's safety as a food additive did
not have major concerns about the product's safety, many of the respondents
reported having some safety-related concerns regarding aspartame.
The GAO's poll results included the responses of sixty-seven medical re-
searchers who rated their condence in aspartame as a harmless food additive.
Only twelve of the sixty-seven researchers who responded to the safety question
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45said that they had major concerns and little, if any, condence in the safety
of aspartame.153 However, more than half of the researchers who responded
said that they had some concerns over safety. Of the remaining respondents,
twenty-nine said that they had few, if any, concerns and were very condent of
the safety of aspartame. Twenty-six researchers said that they were somewhat
concerned but generally condent about the safety of aspartame as a food ad-
ditive.154 Despite the generally positive results of the poll, room for doubt was
not eliminated entirely.
During the next eight years, consumer use of aspartame increased dramatically
as the FDA continued approving he substance for dierent uses.155 Although
the controversy was not the focus of much mainstream media attention for that
period of time, the war was not over. As CNI continued to object to aspartame's
approval, the FDA continued to overrule these objections and deny requests for
additional public hearings regarding the safety of aspartame for use in food.156
Research and related controversy continued on without much mass-media at-
tention until 1996 when John Olney, a physician at the Washington University
Medical School in St. Louis and a long time aspartame critic, completed a study
connecting the use of aspartame to increased rates of brain tumors. Once Dr.
Olney's study was complete, it was published in the Journal of Neuropathy and
Experimental Neurology in November of 1996.157 The Community Nutrition
Institute, along with former senator Metzenbaum, the then head of the Con-
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46sumer Federation of America, took the opportunity to once again raise consumer
awareness of their belief in the dangers of aspartame. CNI and Metzenbaum
held a press conference in at which Metzenbaum said that the FDA had not
done enough to ensure the safety of aspartame.158 Olney's study immediately
engendered media attention and once again heightened skepticism about the
safety of aspartame and concerns about the role of the FDA.
The study preformed by Olney reviewed data on incidences of brain tumors
compiled by the National Cancer Institute. Dr. Olney described his research:
[W]e analyzed these (sic) data from 1975-1992 and found that the brain tu-
mor incidences in the United States occurred in two distinct phases, an early
modest increase that may primarily reect improved diagnostic technology, and
a more recent sustained increase in the incidence and shift toward greater ma-
lignancy that must be explained by some other factor(s). Compared to other
environmental factors putatively linked to brain tumors, the articial sweetener
aspartame is a promising candidate to explain the recent increase... Evidence
potentially implicating aspartame includes...the close temporal association (as-
partame was introduced into U.S. food and beverage markets several years prior
to the sharp increase in brain tumors and malignancy).159
What the media did not latch on to was the study's conclusion that more
studies on the subject were necessary.
Within days of the issuance of Dr. Olney's study results the NutraSweet Kelco
Co., then producer of aspartame, issued a rebuttal charging that the authors
manipulated the National Cancer Institute's data to create an overly dramatized
graph of the rate of increase in brain tumors.160 According to the company,
the increasing brain tumor and mortality rates in the United States and other
countries began before aspartame had been introduced to the general public.
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47Furthermore, the company argued, There is also no association between the
amount of aspartame use and overall brain tumor rates... The use of aspartame
increased dramatically starting in 1983-1984 and continued to increase while the
increase in brain tumor rates decelerated... 161
According to the NutraSweet Kelco Co., there were several problematic ele-
ments of Olney's study. First of all, although Olney used data from the National
Cancer Institute (NCI) on the rate of brain cancer incidence in his study, he
failed to state that it was unknown whether any of the individuals consumed
aspartame. The NCI data shows that the greatest increase in brain tumor inci-
dence was found in the elderly, while the most avid users of aspartame were the
young and the middle aged. Furthermore the NCI data clearly shows that the
rate of brain cancer incidence began leveling o in the mid-eighties, the same
time that aspartame use expanded.162
Standing behind its original decision to approve the use of aspartame as a food
additive, the FDA emphasized the problems with Olney's study. Prompted by
the morass of media attention and consumer hype, the FDA prepared a talk pa-
per disputing the study. The paper, which was released on November 8, 1996,
asserted that the National Cancer Institute's database on cancer incidence did
not support an association between the use of aspartame and increased incidence
of brain tumors.163 According to the FDA, the data from the National Cancer
Institute show that overall incidence of brain and central nervous system cancers
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48began increasing in 1973 and continued to increase through 1985.164 The FDA
argued further that since the 1985 trend line had attened for these cancers,
and decreased slightly in 1991-1993, Olney's study results were awed.165
Other members of the community were equally irate that this controversy had
been revived by what many people felt was unsubstantiated data. Dr. Dim-
itrios Trichopoulous, professor of epidemiology and then director of the Harvard
Center for Cancer Prevention, called the study preposterous.166 Trichopoulous
also said, [T]he arguments of Olney et al. implicitly require two biologically
indefensible assumptions: that a certain factor (aspartame) could cause a solid
tumor (brain cancer) with a latency period of less than four years and that
subsequent widespread exposure to this factor would cause no further increase
in the incidence of that cancer.167 A harsher criticism of Olney and his study
came from Michael Fumento in a Washington Times commentary discussing the
amount of media attention the study had received. Fumento wrote, [T]his is a
study that doesn't deserve the least bit of ink...Dr. Olney could just as easily
have blamed the rise in brain tumors on Ronald Reagan becoming president,
which also occurred in 1981.168
XXI. The Internet's Role in the Aspartame Controversy
Despite widespread agreement between members of the medical, scientic
and government communities that Olney's study did not constitute a signicant
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49addition to the research on aspartame as a food additive, the study did succeed
in re-fueling consumer interest in the possible dangers related to aspartame
consumption. Olney provided additional fodder for the numerous aspartame-
related Internet sites that have appeared in the last ve years.
Today there are a wide variety of web sites that address aspartame related
safety concerns. The site content ranges from panic-driven rhetoric and warn-
ings addressed to all site visitors that tell of the horrors that will result from
aspartame consumption, to the more standard consumer advocacy sites that
tend to provide less myth-generation and hyperbolic information. Because the
Internet is an easy-access forum for people to perform research and express their
own views on dierent topics, it has become a brilliant forum for promoting the
largely unsubstantiated fears regarding the consumption of aspartame. Not only
are there no checks on the accuracy of information on the web, it provides people
the space to voice their own (often irrational) fears about any topic. For ex-
ample, one site temporarily proclaimed, EQUAL KILLS! Because the research
that has been done on aspartame has not concluded that there is absolutely no
possibility that the additive could cause any adverse reaction, there is enough
room for the necessary doubt to keep this controversy alive.
XXII. Conclusion
Since James Schlatter discovered the sweet taste of aspartame in 1965, the food
additive has become one of the most controversial and most consumed food
additives in the United States. It has also been plagued by controversy de-
50rived from myriad sources. From the beginning, aspartame had to enter into
the already controversial low-calorie sweetener industry that was tarnished by
concerns over the safety of saccharine. It then was the subject of poorly han-
dled research that was supposed to determine whether or not aspartame was safe
for human consumption. Even though the studies demonstrated that aspartame
was safe, these conclusions were questioned because of the sloppy research meth-
ods employed. Once the FDA had nally reviewed all the data of the task force
as well as some additional studies and concluded that aspartame was indeed
safe for human consumption, the controversy that had attached to aspartame
spread to the FDA as well.
FDA's approval of aspartame for human consumption, and the agency's tenacity
in holding on to its position on this matter led to a heightened level of public
scrutiny of the agency as well as increasingly virulent attacks on aspartame. It
also led to the solidication of some extraordinarily passionate consumer advo-
cates, such as Dr. John Olney, who made it their mission to remove aspartame
from the shelves of American grocery stores. As a group, these people con-
tributed to the attempts of CNI to have judges overrule the FDA's holdings on
the aspartame issue, and to generally stir up negative publicity about aspartame
and its supposed dangers.
Despite the impressive attempts of CNI and other consumer advocates to dampen
consumer enthusiasm for aspartame, consumption of aspartame and other low-
calorie sweeteners has continued to increase in the United States. Although it
is not easy to determine whether this increasing use of aspartame can be at-
51tributed to simple consumer desire for the product, or market demand combined
with a certain level of widespread trust in the ability of the FDA to do its job.
It seems likely that the high level of market demand for aspartame would not
exist without a combination of trust in the FDA and desire for a low calorie
sugar substitute.
The extensive research into the history of aspartame done for this paper has
dispelled many of the myths that are commonly associated with the food ad-
ditive and its potential dangerous side eects. Although there are merits to
having forums such as Internet sites and public hearings in which consumers
can express their thoughts and concerns about a wide range of topics including
fears about aspartame side eects, there are damaging consequences to having
these easy-access forums as well. As the controversy surrounding aspartame
has petered out in governmental forums for example, it has once again ared
through scare tactics amongst consumers. The Internet provides the public with
access to enormous amounts of data, but that data is oftentimes one-sided and
not entirely reliable. Hopefully, as the Internet develops and is increasingly used
as a research tool, more accurate information about controversies, such as the
history of aspartame, will be accessible. Once this goal is achieved, consumers
will have access to a much more complicated, and much more accurate pool of
information on which to base their personal decisions.
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